Comprehensive Respiratory Virus Panel
Superior Success Rate even with Low Amounts of Clinical Sample
Overview
Respiratory Viral WGS with Celemics Comprehensive Respiratory Virus Panel
Detection panel for the accurate sequencing and identification of prominent whole viral genomes, including SARS-CoV-2 mutations and variants (ex. Omicron, Delta).
Viruses are continuously evolving in ways that make them increasingly infectious and difficult to cure. Thus, the discovery of specific disease-causing viral strains and research into their ability to spread within individuals in a given population have become a paramount public health issue. The Celemics Comprehensive Respiratory Virus Panel (CRV Panel) was developed to detect and sequence respiratory disease-causing viruses in humans using the NCBI RefSeq database as its foundation. It allows for the Whole Genome Sequencing of SARS-CoV-2 and all its relevant mutations and variants, and enables simultaneous testing of 9 different virus types and its 39 strains of clinically significant and prevalent respiratory viruses.
Provision of 9 different, 39 different strains of viruses, including SARS-CoV-2 Whole genome sequence
The comprehensive respiratory panel is designed to provide whole genome sequences for 39 different strains of respiratory viruses, including SARS-CoV-2 and all related mutations as well as opportunities for other novel variant detection.
With Celemics’ branded technologies, we provide exceptional success rate of respiratory virus detection and whole viral genome sequencing.
Exceptional Variant Detection Success Rate and WGS even in Low- viral Load Clinical Sample
The CRV panel ensures to provide superior WGS success rate and pathogen classification even with poor quality specimen, such as low viral load clinical specimen or poor quality environment-originated samples. Using Celemics’ CRV panel, you will witness the robust pathogen detection accuracy with significantly reduced gap formation compared to other competitor products.
Excellent and high coverage from clinical samples using CRV Panel
The performance test results from clinical samples show excellent Whole Genome coverage.
| Sample Type | Coverage (1X) | Coverage (10X) | Coverage (100X) |
|---|---|---|---|
| Clinical specimen | 99.95% | 99.87% | 98.95% |
Mutation Frequency and Genomic Structure of SARS-CoV-2 Variants
Coverage of Wide Range of Respiratory Pathogens
Celemics’ CRV panel is designed to assess wide range of respiratory pathogens. The panel will allow whole genome sequencing of 39 strains for 9 different virus types (SARS-CoV-2 solo analysis is also possible); includes all types of respiratory virus that are commonly assessed by medical institutions around the globe. Using the panel, you can evaluate double pandemic or co-infection in a single assay.
Easy assessment of numerous respiratory pathogens
※ Celemics provides stand-alone SW for BI analysis, allowing customers to access detailed data analysis information and ensuring the security of client sequence information.
SARS-CoV-2 Genome Coverage
1X Coverage
Virus Distribution / Virus Depth
Other Features
User-friendly Celemics
Virus Verifier
Celemics’ own stand-alone Bioinformatics SW for easy data analysis
Simple Workflow with
All-inclusive Kits
Shorter hybridization time with Celemics ‘Enhancer’ Solution
Ready to use double-stranded cDNA synthesis kit
Flexible Integration on
Various Sequencing Platform
Compatible with various sequencer; made possible with Celemics’ chemistry optimization and blocker technology
Workflow
Inclusive preparation kit provided directly from Celemics
Portions of the procedure covered through the Complete Kit are highlighted in Red Competitors: 16 hours (Target Enrichment step, Hybridization Capture)
01
RNA extraction
02
NGS Iibrary Preparation
cDNA synthesis, NGS Prep.
~5 hours
03
Target enrichment
Hybridization capture
~ 4 hours
04
Sequencing
All Illumina and Thermo Fisher Scientific Sequencers
Depending on read length
05
Data analysis
Virus Data Report
~ 3 hours
01
RNA extraction
02
NGS Iibrary Preparation
cDNA synthesis, NGS Prep.
~5 hours
03
Target enrichment
Hybridization capture
~ 4 hours
04
Sequencing
All Illumina and Thermo Fisher Scientific Sequencers
Depending on read length
05
Data analysis
Virus Data Report
~ 3 hours
Specification
“CRV Panel Specification”
| Target Virus | 9 types / 39 virus strains, including SARS-CoV-2 |
|---|---|
| Target Size | 706 Kb |
| Mutation Analysis | Variant detection, Viral mutation (SNV, Indel) from generated Whole Genome Sequence |
| Sample Type | URT, NP/OP, etc. |
| Platform | All Illumina and Thermo Fisher Scientific Sequencers |
| Kit Composition | Provides all required reagents, including RNA to cDNA kit, cDNA to captured library kit, and bioinformatics SW |
| Bioinformatics Pipeline | Stand-alone bioinformatics SW 'Celemics Virus Verifier' ( FASTQ to Visual Report ) |
Specification - Pathogen List
| Human Adenovirus | Coronavirus | Parainfluenza Virus | Respiratory Syncytial Virus |
|---|---|---|---|
| Human Adenovirus Type 1 (HAdV-C1) | Coronavirus HKU1 | Parainfluenza 1 (PIV 1) | Respiratory Syncytial Virus A (RSV A) |
| Human Adenovirus Type 2 (HAdV-C2) | Coronavirus NL63 | Parainfluenza 2 (PIV 2) | Respiratory Syncytial Virus B (RSV B) |
| Human Adenovirus Type 3 (HAdV-B3) | Coronavirus 229E | Parainfluenza 3 (PIV 3) | Human Metapneumovirus |
| Human Adenovirus Type 4 (HAdV-E4) | Coronavirus OC43 | Parainfluenza 4 (PIV 4) A | |
| Human Adenovirus Type 5 (HAdV-C5) | SARS-CoV-2 | Parainfluenza 4 (PIV 4) B | |
| Human Adenovirus 7 (HAdV-B7) | |||
| Human Adenovirus 14 (HAdV-B14 | Human Enterovirus | Human Rhinovirus (A/B/C) | |
| Human Adenovirus 21 (HAdV-B21) | Influenza A | EV-C104 | Human Rhinovirus A |
| Influenza A-H7 Virus (Flu A-H7) | EV-C105 | Human Rhinovirus B | |
| Bocavirus 1/2/3/4 (HBoV) | Influenza A-H1 Virus (Flu A-H1) | EV-C109 | Human Rhinovirus C |
| Human Bocavirus 1 | Influenza A-H3 Virus (Flu A-H3) | EV-C117 | |
| Human Bocavirus 2 | EV-C118 | ||
| Human Bocavirus 3 | Influenza B | CV-A21 | |
| Human Bocavirus 4 | Influenza B Virus (Flu B) | EV-D68 |
Related Products
Stabilize RNA to double-stranded cDNA for unquestionable performance
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Stabilize RNA to double-stranded cDNA for unquestionable performance
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Resources
Technical Resources
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_Comprehensive Respiratory Virus Panel_Illumina
MSDS_Comprehensive Respiratory Virus Panel_Thermo Fisher
MSDS_Comprehensive Respiratory Virus Panel_MGI
References
Scientific Reports
Natural fatal infection of Tembusu virus in bottlenose dolphins in Thailand
Piewbang, C., Yi, L., Zahro, A. N., Poonsin, P., Panyathi, P., Kasantikul, T., … & Techangamsuwan, S. (2025). Natural fatal infection of Tembusu virus in bottlenose dolphins in Thailand. Scientific Reports, 15(1), 9917.
10.1038/s41598-025-93477-5
PLOS ONE
Molecular epidemiology and phylogenetic insights of lumpy skin disease in cattle from diverse agro-ecological regions of Punjab, Pakistan
Jabbar, M. H., Atif, F. A., Kashif, M., Ahmed, I., Iarussi, F., & Swelum, A. A. (2025). Molecular epidemiology and phylogenetic insights of lumpy skin disease in cattle from diverse agro-ecological regions of Punjab, Pakistan. PloS one, 20(1), e0315532.
10.1371/journal.pone.0315532
Journal of Global Antimicrobial Resistance
Therapeutic potential of novel phages with antibiotic combinations against ESBL-producing and carbapenem-resistant Escherichia Coli
Shamsuzzaman, M., Kim, S., & Kim, J. (2025). Therapeutic Potential of Novel Phages with Antibiotic Combinations Against ESBL-Producing and Carbapenem-Resistant Escherichia coli. Journal of Global Antimicrobial Resistance.
10.1016/j.jgar.2025.04.005
International Journal of Arrhythmia
Clinical role of genetic testing for the Brugada syndrome overlapping with arrhythmogenic cardiomyopathy
Jeong, J. H., Lee, H. S., Choi, Y. Y., Kim, Y. G., Shim, J., Hwang, J. H., … & Choi, J. I. (2024). Clinical role of genetic testing for the Brugada syndrome overlapping with arrhythmogenic cardiomyopathy. International Journal of Arrhythmia, 25(1), 12.
10.1186/s42444-024-00121-w